The most promising and consistent coaguligands in tumor targeting to date have utilized the dual targeting NGR and self-amplifying CREKA peptide, however it is somewhat difficult to compare target efficacy with the use of multiple different ligands and procoagulant combinations, across multiple cancer models. Here, RTN4R is linked to neoplasm.